Sulfinpyrazone has 14 known drug interactions based on U.S. FDA drug labeling data. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Enoxaparin Sodium, Nitrofurantoin, Nitrofurantoin (Monohydrate/Macrocrystals). Patients taking Sulfinpyrazone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 14
- Major
- 7
- Moderate
- 7
Major (7)
- Sulfinpyrazone + Enoxaparin Sodium— May enhance risk of hemorrhage. Discontinue prior to Lovenox initiation if possible, or conduct close clinical and labor…
- Sulfinpyrazone + Nitrofurantoin— Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary l…
- Sulfinpyrazone + Nitrofurantoin (Monohydrate/Macrocrystals)— Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary l…
- Sulfinpyrazone + Nitrofurantoin Monohydrate— Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary l…
- Sulfinpyrazone + Nitrofurantoin Monohydrate/Macrocrystalline— Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary l…
- Sulfinpyrazone + Warfarin— CYP2C9 inhibitor that increases warfarin effect and INR; requires close INR monitoring
- Sulfinpyrazone + Warfarin Sodium— CYP2C9 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.
Moderate (7)
- Sulfinpyrazone + Aspirin And Extended - Release Dipyridamole— Salicylates antagonize the uricosuric action of sulfinpyrazone.
- Sulfinpyrazone + Butalbital, Aspirin, And Caffeine— Aspirin diminishes effectiveness of uricosuric agents in gout treatment by competing for protein binding sites.
- Sulfinpyrazone + Glimepiride— May increase glucose-lowering effect of glimepiride, increasing susceptibility to and/or intensity of hypoglycemia.
- Sulfinpyrazone + Nateglinide— CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and…
- Sulfinpyrazone + Salicylic Acid— Salicylate inhibits the uricosuric effect of sulfinpyrazone.
- Sulfinpyrazone + Salicylic Acid 10%— Salicylate inhibits the uricosuric effect of sulfinpyrazone.
- Sulfinpyrazone + Salsalate— Salicylate competes with sulfinpyrazone for protein binding sites, potentially affecting drug levels.